论文部分内容阅读
阿糖胞苷(Ara-C)是治疗急性白血病(AL)及非何杰金淋巴瘤(NRL)最重要的药物之一。1982～1987年间,211例AL或NHL患者在荷兰来登大学医疗中心接受了以Ara-C为主要药物、共461疗程的治疗。36例患者在治疗期间或疗程结束时发生胃肠道合并症,其中24例接受26次胃肠道普通X线照象检查,作者对检查结果及其患者临床表现进行了分析。 15例为AML,5例为ALL,4例为NHL。26次X线照象,麻痹性肠梗阻18例(73％)、盲肠扩张10例(38％)、肠积气症7例(27％)、小肠襻增厚5例(19％)、气腹2例(8％)。临床表现为麻痹性肠梗阻
Ara-C is one of the most important drugs for treating acute leukemia (AL) and non-Hodgkin’s lymphoma (NRL). Between 1982 and 1987, 211 patients with AL or NHL received treatment with Ara-C as the main drug for a total of 461 courses at the University Medical Center in the Netherlands. Thirty-six patients developed gastrointestinal complications during treatment or at the end of the course of treatment. Twenty-four patients underwent 26 general gastrointestinal tract X-ray examinations. The authors analyzed the findings and their clinical manifestations. 15 cases were AML, 5 cases were ALL, and 4 cases were NHL. 26 X-rays, 18 cases of paralytic ileus (73%), 10 cases of cecum expansion (38%), 7 cases of intestinal gas disease (27%), 5 cases of small bowel hernia (19%), qi There were 2 cases of abdominal (8%). Clinical manifestations of paralytic ileus